Compare Recursion Pharmaceuticals Inc (RXRX) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.82 (market cap $3.16B). The key difference: Invesco S&P 500 High Div Low Volatility ETF is the larger of the two by market cap, and Recursion Pharmaceuticals Inc is more actively traded (40,478,768 versus 1,245,780). Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| RXRX | SPHD | |
|---|---|---|
Market Cap | $2.31B | $3.16B |
Volume | 40,478,768 | 1,245,780 |
Sector | Health | — |
52-Week High | $6.79 | $53.55 |
52-Week Low | $2.84 | $46.96 |
Typical Hold Time | 22 Days | 125 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
SPHD trades at $48.19, down 0.58% with a bearish technical outlook showing 17 sell signals versus 4 buy signals. The ETF maintains its high-dividend focus with recent payouts of $0.20-$0.21, though financial ratios remain unavailable. Technical indicators show oversold conditions with RSI at 6.33-14.37 levels while moving averages signal continued downward pressure.
The ETF faces headwinds from underperformance concerns versus peers like SCHD, with media highlighting decade-long return disparities. While monthly dividends appeal to income investors, the lack of quality screening in stock selection poses yield trap risks. Current sentiment leans cautious as analysts question the fund's total return potential amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
